alzheimer's $\mathfrak R$ association

2008 Alzheimer's Association Grants Portfolio

—Organized by trends in research

Biology of disease-related molecules

1. Production of beta-amyloid

• Willem G. Annaert, Ph.D.

Flanders Interuniversity Institute for Biotechnology Leuven, Belgium

Targeting and Localization of Distinct Gamma-Secretase Complexes Versus APP

Investigator-Initiated Research Grant—\$240,000 over three years Which variant form of gamma-secretase targets APP?

• Bing Gong, M.D.

Mount Sinai School of Medicine New York, New York *Fbx2-Mediated Ubiquitin Pathway: A Novel Route for BACE1*

Degradation

Investigator-Initiated Research Grant—\$240,000 over three years What mechanism regulates levels of a protein involved in beta-amyloid production?

• Yong-Keun Jung, Ph.D.

Seoul National University

Seoul, South Korea

Novel Activator Genes of Gamma-Secretase (SecAs) for APP-Favorable Cleavage

Investigator-Initiated Research Grant—\$240,000 over three years Do certain proteins activate gamma-secretase to target and process APP?

• David E. Kang, Ph.D.

University of California, San Diego La Jolla, California

Targeting the LRP Pathway for Abeta Reduction From Inside and Outside

Investigator-Initiated Research Grant—\$240,000 over three years How does APP interaction with another protein promote the production of beta-amyloid?

• Seong-Hun Kim, M.D., Ph.D.

University of Florida

Gainesville, Florida

Role of Rer1 in the Regulation of Gamma-Secretase Trafficking and Activity

Investigator-Initiated Research Grant—\$240,000 over three years How does a certain protein's regulation of gamma-secretase activity contribute to beta-amyloid production?

• Yueming Li, Ph.D.

Sloan-Kettering Institute for Cancer Research New York, New York

Modulation of the Gamma-Secretase Complex and Activity by Individual Subunits

Investigator-Initiated Research Grant—\$240,000 over three years How do presenilin proteins work with other enzymes to promote excessive beta-amyloid production?

Peter T. Nelson, M.D., Ph.D.

University of Kentucky Research Foundation Lexington, Kentucky

Mechanism and Therapeutic Significance of an Alzheimer's Disease– Relevant MicroRNA Pathway

New Investigator Research Grant—\$100,000 over two years Does inhibition of a certain brain chemical decrease the expression of a gene encoding a key protein in beta-amyloid production?

Masuo Ohno, Ph.D.

Nathan S. Kline Institute for Psychiatric Research Orangeburg, New York

Testing of Rab5-Overexpressing Mice as a Novel Alzheimer's Disease Model

Investigator-Initiated Research Grant—\$240,000 over three years How might a certain protein contribute to the abnormal trafficking of APP and subsequent beta-amyloid production?

• Davide Tampellini, Ph.D.

Joan & Sanford I. Weill Medical College of Cornell University New York, New York *Study of the Relation Between Synaptic Activity and Amyloid-Beta* New Investigator Research Grant—\$99,660 over two years How does synaptic activity affect the production and transport of betaamyloid?

• Gopal Thinakaran, Ph.D.

University of Chicago Chicago, Illinois Altering Microdomain Localization of Gamma-Secretase in Transgenic Mice Investigator-Initiated Research Grant—\$240,000 over three years

How do factors controlling the location of gamma-secretase in a cell mediate beta-amyloid production?

• Kulandaivelu S. Vetrivel, Ph.D.

University of Chicago

Chicago, Illinois

Exploring Beta-Secretase Activity in Lipid Raft Microdomains New Investigator Research Grant—\$100,000 over two years What role do certain proteins play in transporting and locating enzymes involved in beta-amyloid production?

• Sungok Yoon, Ph.D.

Ohio State University Research Foundation Columbus, Ohio

The Role of JNK3 in APP Trafficking

Investigator-Initiated Research Grant—\$214,800 over three years How does a protein's trafficking of APP in a cell influence beta-amyloid production?

2. Formation of neurofibrillary tangles

• Koichi Iijima, Ph.D.

Thomas Jefferson University Philadelphia, Pennsylvania Mechanisms of Tau Phosphorylation and Toxicity Induced by Abeta42 In Vivo

New Investigator Research Grant—\$99,999 over two years What enzymes mediate beta-amyloid–induced abnormal chemical changes in tau proteins?

• Fei Liu, Ph.D.

Research Foundation for Mental Hygiene, Inc. at New York State Institute for Basic Research Staten Island, New York

Involvement of Dyrk1A in ASF-Regulated Alternative Splicing of Tau Exon 10

New Investigator Research Grant—\$100,000 over two years How do certain proteins regulate the production of variant tau proteins susceptible to tangle formation?

• Jaya Padmanabhan, Ph.D.

Johnnie B. Byrd, Sr. Alzheimer's Center and Research Institute, Inc. Tampa, Florida

Regulatory Functions of Inflammatory Proteins in Alzheimer's Disease

Investigator-Initiated Research Grant—\$240,000 over three years Do inflammatory proteins help regulate disease-related alterations of the tau protein?

3. Normal function of disease-related proteins

• Olav Andersen, Ph.D.

University of Aarhus Aarhus, Denmark

Influence on APP Processing by the Sorting Complex of SorLA and Retromer

New Investigator Research Grant—\$100,000 over two years How do certain proteins normally regulate the trafficking of APP and other proteins in neurons?

• Andrew F. Hill, Ph.D.

University of Melbourne

Parkville, Australia

Investigating Exosomes as Novel Secretory Carriers of APP and Abeta New Investigator Research Grant—\$99,000 over two years How does certain cellular "machinery" secrete APP and beta-amyloid from neurons?

• Ipe Ninan, Ph.D.

New York University School of Medicine

New York, New York

Modulation of Synaptic Neurotransmission by Physiological Amyloid-Beta

New Investigator Research Grant—\$99,956 over two years What role do healthy levels of beta-amyloid play in cell function and cell-to-cell communication?

Alzheimer's disease pathology

1. Properties and toxicity of abnormal protein structures

• Yoshitaka Ishii, Ph.D.

University of Illinois - Chicago

Chicago, Illinois

Toxicity and Structure of Aggregated Alzheimer Beta-Amyloid Investigator-Initiated Research Grant—\$240,000 over three years What are the toxic and structural properties of various beta-amyloid aggregates?

• Matt Kaeberlein, Ph.D.

University of Washington Seattle, Washington

TOR Signaling in Amyloid Beta Toxicity

How does TOR (target of rapamycin) kinase affect amyloid beta toxicity?

• Bruce T. Lamb, Ph.D.

Cleveland Clinic Foundation Cleveland, Ohio

A Humanized Mouse Model of Alzheimer's Disease

Investigator-Initiated Research Grant—\$240,000 over three years What can be learned about beta-amyloid-tau interactions in a novel genetic mouse model of Alzheimer's disease?

- Bradley Linden Nilsson, Ph.D.
 - University of Rochester Rochester, New York *Probing Amyloid-Beta Structure and Aggregation With Non-Natural Amino Acids* New Investigator Research Grant—\$99,998 over two years How does beta-amyloid folding affect its aggregation and toxicity?
- Einar M. Sigurdsson, Ph.D.

New York University School of Medicine New York, New York *Tau Pathology: Therapy and In Vivo Imaging* Will a new in vivo imaging technique clarify the neurotoxic effects of the tau protein?

Michael S. Wolfe, Ph.D.
Brigham and Women's Hospital

Boston, Massachusetts **Regulation of RNA Splicing in Alzheimer's and Related Dementias** Zenith Fellows Award—\$450,000 over three years How might errors in the "translation" of genetic instructions result in toxic forms of beta-amyloid and tau?

2. Mediators of beta-amyloid toxicity

• Gilles J. Guillemin, Ph.D.

University of New South Wales Sydney, Australia

Identification of a New Neurodegenerative Mechanism in Alzheimer's Disease

Investigator-Initiated Research Grant—\$228,453 over three years What intermediary role does a certain protein play in beta-amyloid's toxic effect on cells?

• Giulio Taglialatela, Ph.D.

University of Texas Medical Branch at Galveston Galveston, Texas

Neurobehavioral Toxicity of Natural Amyloid-Beta Oligomers Investigator-Initiated Research Grant—\$240,000 over three years How does a certain protein mediate the toxic effect of small betaamyloid structures?

• Henrik Zetterberg, M.D., Ph.D.

Göteborg University Molndal, Sweden *Targeted Proteomics of Cerebrospinal Fluid Amyloid-Beta Fragments in Alzheimer's Disease* New Investigator Research Grant—\$100,000 over two years What mechanism regulates the accumulation of beta-amyloid in cerebrospinal fluid in Alzheimer's disease?

3. Synaptic dysfunction: Loss of cell-to-cell communication

• Guojun Bu, Ph.D.

Washington University in St. Louis St. Louis, Missouri LRP1 and ApoE Isoforms in Brain Lipid Metabolism and Synaptic Functions

Zenith Fellows Award—\$450,000 over three years How do variant forms of an Alzheimer risk gene affect the function of a protein that plays a role in maintaining synapses?

• Gilbert Di Paolo, Ph.D.

Columbia University Medical Center New York, New York

Genetic Modulation of PIP2 in Alzheimer's Disease Mouse Models: Effect on Cognitive Decline

New Investigator Research Grant—\$100,000 over two years Do beta-amyloid oligomers cause synaptic dysfunction by targeting a certain cell-membrane protein?

• Wen-Biao Gan, Ph.D.

New York University School of Medicine New York, New York The Role of Microglia in Amyloid Plaque Clearance and Synaptic Pathology

Investigator-Initiated Research Grant—\$240,000 over three years How do supporting brain cells affect synaptic function and dysfunction?

• Nashaat Gerges, Ph.D.

Medical College of Wisconsin

Milwaukee, Wisconsin

Role of Neurogranin in Alzheimer's Disease

New Investigator Research Grant—\$100,000 over two years How does beta-amyloid alter the properties and function of a protein essential for cell-to-cell communication?

• Kwang Mook Jung, Ph.D.

University of California, Irvine Irvine, California

Deficits in Anandamide Signaling Underlie Cognitive Dysfunction in Alzheimer's Disease

Investigator-Initiated Research Grant—\$239,714 over three years Do beta-amyloid–induced alterations of a protective brain chemical result in synaptic dysfunction?

• Peter Penzes, Ph.D.

Northwestern University

Chicago, Illinois

Modeling Synapse Dysgenesis–Linked Memory Impairment in Alzheimer's Disease

Investigator-Initiated Research Grant—\$239,764 over three years How might structural changes in neurons account for the link between synaptic dysfunction and memory impairment in Alzheimer's disease?

• Subhojit Roy, Ph.D.

University of California, San Diego San Diego, California

Mechanisms of Axonal Transport Dysfunction in Alzheimer's Disease New Investigator Research Grant—\$100,000 over two years How might amyloid-induced damage to a cell's nutrient-transport network disrupt synaptic function?

4. Mitochondrial dysfunction: Impairment in cells' energyproducing structures

• Anand Hindupur, Ph.D.

University of Pennsylvania

Philadelphia, Pennsylvania

Mechanisms Underlying the Biogenesis of Mitochondrial Abeta Investigator-Initiated Research Grant—\$240,000 over three years How does beta-amyloid affect a brain cell's energy-producing structures?

• Qingli Shi, Ph.D.

Winifred Masterson Burke Medical Research Institute White Plains, New York

Oxidative Stress/Gene Regulation of Mitochondrial Enzymes Implicated in Alzheimer's Disease

New Investigator Research Grant—\$100,000 over two years How might toxic oxygen molecules disrupt the function of proteins in a neuron's energy-producing structures?

• Shi Du Yan, M.D.

Columbia University New York, New York

Cyclophilin D as a Mitochondrial Target of Alzheimer's Disease Investigator-Initiated Research Grant—\$240,000 over three years How might a certain protein contribute to energy-producing dysfunction in neurons in Alzheimer's disease?

5. Function and dysfunction of neuroprotective factors

• Jason Eriksen, Ph.D.

University of Houston Houston, Texas *Role of PGRN in Microglial Activity in Alzheimer's Disease* New Investigator Research Grant—\$99,970 over two years What mediating role might a certain protein play between toxic Alzheimer agents and dysfunctional "janitorial" processes in neurons?

• Stanislav L. Karsten, Ph.D.

Los Angeles Biomedical Research Institute at Harbor – UCLA Medical Center Torrance, California *Neuroprotective Role of Puromycin-Sensitive Aminopeptidase (PSA)* New Investigator Research Grant—\$100,000 over two years What role does a certain protein play in the removal of excess or abnormal tau from neurons?

• David M. Lin, Ph.D.

Cornell University Ithaca, New York *A Novel Mouse Model of Neurodegeneration* Investigator-Initiated Research Grant—\$240,000 over three years How might the disruption of helper cells in the brain contribute to the degeneration of neurons?

• Helene Marie, Ph.D.

European Brain Research Institute Rome, Italy

Does NGF Deprivation Lead to Glutamatergic/GABAergic Network Imbalance?

New Investigator Research Grant—\$98,450 over two years How might a decline in a neuroprotective protein lead to a chemical imbalance in neurons in Alzheimer's disease?

• Robert A. Marr, Ph.D.

Rosalind Franklin University of Medicine and Science North Chicago, Illinois *Investigation of the Role of MMEL in Protection From*

Alzheimer's Disease

New Investigator Research Grant—\$239,999 over two years What is the role of a beta-amyloid–degrading enzyme in protecting brain cells?

• William Mobley, M.D., Ph.D.

Stanford University

Stanford, California

Degeneration of Hippocampal Circuits in Down Syndrome: a Role for APP?

Investigator-Initiated Research Grant—\$239,901 over three years Does APP disrupt a neuron's ability to use protective proteins?

Nicholas W. Seeds, Ph.D.

University of Colorado Denver, Anschutz Medical Campus Aurora, Colorado

Plasminogen Activator and Its Inhibitors in Alzheimer's Disease

Investigator-Initiated Research Grant—\$200,000 over three years What factors inhibit normal beta-amyloid–degrading functions in the brain?

• Dengshun Wang, M.D., Ph.D.

University of Wisconsin–Madison Madison, Wisconsin

Identifying Pathophysiologically Relevant Amyloid-Beta–Degrading Enzyme in Alzheimer's Disease

Investigator-Initiated Research Grant—\$240,000 over three years Does impairment of beta-amyloid–degrading enzymes contribute to the accumulation of beta-amyloid in Alzheimer's disease?

• Ronald Wetzel, Ph.D.

University of Pittsburgh Pittsburgh, Pennsylvania

The Role of Amyloid-Beta Aggregate Polymorphism in Alzheimer's Disease

Investigator-Initiated Research Grant—\$240,000 over three years How might amyloid plaque function to sequester toxic amyloid in the brain?

• Dun-Sheng Yang, Ph.D.

Nathan S. Kline Institute for Psychiatric Research Orangeburg, New York

Rescue Autophagic-Lysosomal Protein Degradation to Reverse Amyloid Pathology

Investigator-Initiated Research Grant—\$239,968 over three years Does repair of a neuron's internal "waste management" system reverse beta-amyloid–induced cell damage?

• Ryohei Yasuda, Ph.D.

Duke University Medical Center Durham, North Carolina

Amyloid-Beta Induced Rho GTPase Signaling in Dendritic Spines New Investigator Research Grant—\$100,000 over two years

How does beta-amyloid affect enzymes responsible for maintaining a neuron's dendrites, or long branching arms?

6. Disruption of other brain cell functions and properties

• Bernardo Rudy, M.D., Ph.D.

New York University School of Medicine New York, New York

Neocortical Cholinergic Function in Alzheimer's Mouse Models Investigator-Initiated Research Grant—\$198,000 over three years How does the dysfunction of specialized neurons contribute to symptoms of Alzheimer's disease?

• Grace Stutzmann, Ph.D.

Rosalind Franklin University of Medicine and Science North Chicago, Illinois

Neuronal Ca2+ Dysregulation as a Pathogenic Factor in Alzheimer's Disease

New Investigator Research Grant—\$100,000 over two years How might the dysregulation of calcium levels in neurons affect the function of cellular processes linked to Alzheimer's disease?

• Michele Zoli, M.D.

Università di Modena e Reggio Emilia Modena, Italy

Genetic Deletion of Hippocampal Precursors in a Transgenic Model of Alzheimer's Disease

Investigator-Initiated Research Grant—\$198,000 over three years How does Alzheimer's disease influence the normal generation of new nerve cells in the hippocampus?

7. Inflammation

Sergey Kalinin, M.D. University of Illinois at Chicago Chicago, Illinois *Locus Coeruleus Damage During Normal Aging and in Transgenic Models of Alzheimer's Disease* New Investigator Research Grant—\$99,999 over two years How does inflammation affect cells in a vulnerable region of the brain in normal and Alzheimer-like aging mice?

• Lih-Fen Lue, Ph.D.

Sun Health Research Institute Sun City, Arizona Deficiency of Circulating Soluble Receptor RAGE in Subjects With Mild Cognitive Impairment Investigator-Initiated Research Grant—\$238,843 over three years Does reduction of an immune-system protein increase the risk of Alzheimer-related inflammation and disease progression?

• Susan O. McGuire, Ph.D.

Loyola University of Chicago Maywood, Illinois Loss of C5L2 and NFT Formation: Conversion of Mild Cognitive Impairment to Alzheimer's Disease

Investigator-Initiated Research Grant—\$239,323 over three years Does the loss of brainstem cells critical for suppressing inflammation contribute to the progression of Alzheimer's disease?

• Susanna Rosi, Ph.D.

University of California, San Francisco

San Francisco, California Altered Neuronal-Microglia Communication Impacts

Neuronal Function

New Investigator Research Grant—\$100,000 over two years By what mechanisms might inflammation disrupt neuron function and cell-to-cell communication?

• Volney Sheen, M.D., Ph.D.

Beth Israel Deaconess Medical Center Boston, Massachusetts *In Vitro Modeling of Neuronal-Glial Interactions in Alzheimer's Disease* New Investigator Research Grant—\$99,990 over two years By what mechanism does an inflammation-related protein contribute to cell dysfunction or death?

8. Cardiovascular factors in Alzheimer's disease

• Angela L. Jefferson, Ph.D.

Boston University Boston Massachusetts

Left Ventricular Function and Mild Cognitive Impairment Investigator-Initiated Research Grant—\$240,000 over three years Does dysfunction of the heart's main pumping chamber contribute to deficits in brain function?

• James McCallum Noble, M.D.

Columbia University Medical Center New York, New York

Arteriosclerosis and Alzheimer's in a Multiethnic Group of Autopsy Brains

New Investigator Research Grant—\$95,501 over two years What is the relationship between the severity of hardened arteries and severity of dementia?

• Henry Rusinek, Ph.D.

New York University School of Medicine New York, New York Hippocampal Blood Flow and Vascular Reactivity in Normal Aging and Alzheimer's Disease

Investigator-Initiated Research Grant—\$239,941 over three years Can abnormal blood flow in a memory-related region of the brain predict neurodegeneration in that region?

• Aad Van Der Lugt, Ph.D.

Erasmus Medical College

Rotterdam, Netherlands

Arterial Calcifications and Risk of Dementia

New Investigator Research Grant—\$100,000 over two years What contribution does blood vessel damage make to cognitive decline and neurodegenerative diseases?

9. Other factors in Alzheimer pathology

• Adriana Ferreira, Ph.D.

Northwestern University Chicago, Illinois

Cholesterol and the Susceptibility of Aging Neurons to ABeta Toxicity Investigator-Initiated Research Grant—\$240,000 over three years Do levels of cholesterol in neurons increase as neurons age and in turn cause increased cleavage of the protein tau, neuronal degeneration and cell death?

• Lawrence S. Honig, M.D., Ph.D.

Columbia University Medical Center New York, New York

Changes in Telomere Length and the Risk of Alzheimer's Disease Investigator-Initiated Research Grant—\$240,000 over three years Does the shortening of end regions of chromosomes contribute to the onset and progression of Alzheimer's disease?

• Yoshihiro Konishi, M.D., Ph.D.

National Hospital Organization Tottori Medical Center Tottori, Japan

Comparison of Beta-Secretase Between Alzheimer Brain in the United States and Japan

New Investigator Research Grant—\$96,000 over two years How might beta-amyloid pathology differ between populations with significantly different diet and lifestyle practices?

- Mary Jo LaDu, Ph.D.
 - University of Illinois Chicago Chicago, Illinois

The Effect of ApoE Isoform on Intraneuronal ApoE/Abeta42 Interactions

Zenith Fellows Award—\$450,000 over three years What is the effect of variant forms of an Alzheimer risk gene on its protein products' interactions with beta-amyloid?

• Terri Monk, M.D.

Duke University Medical Center Durham, North Carolina *Does Inhalational Anesthesia Accelerate Postoperative Cognitive Decline?* Investigator-Initiated Research Grant—\$240,000 over three years Do certain forms of general anesthesia contribute to cognitive decline after surgery?

• Ken A. Paller, Ph.D.

Northwestern University

Evanston, Illinois Memory Processing During Sleep in Alzheimer's Disease

Investigator-Initiated Research Grant—\$240,000 over three years Do people with Alzheimer's disease experience disruption of memory processing during sleep?

• Sanjay W. Pimplikar, Ph.D.

Cleveland Clinic Foundation Cleveland, Ohio

The Role of APP Intracellular Domain in Neuronal Excitotoxicity Investigator-Initiated Research Grant—\$240,000 over three years How does a portion of APP contribute to an overstimulation of neurons linked to neuron damage and death?

• Rebecca J. Rylett, Ph.D.

University of Western Ontario London, Ontario, Canada

Modulation of Neuronal Gene Expression by Choline Acetyltransferase

Investigator-Initiated Research Grant—\$240,000 over three years What role does an enzyme play in gene expression patterns that may make certain cells vulnerable in Alzheimer's disease?

• John Seibyl, M.D.

Institute for Neurodegenerative Disorders New Haven, Connecticut *Imaging Noradrenergic Function in Alzheimer's Disease* Investigator-Initiated Research Grant—\$236,544 over three years How does Alzheimer's disease affect specialized cells in the brainstem over time?

Dementia risk factors

• Jeffery B. Allen, Ph.D.

Wright State University Dayton, Ohio

Impact of Quality of Education on Cognitive Status of African-American Elders

Investigator-Initiated Research Grant—\$185,526 over three years What impact does education quality and literacy have on the cognitive and adaptive functioning of older African-Americans?

• Natalia A. Crivello, Ph.D.

Tufts University Boston, Massachusetts Folate Deficiency, Brain Lipids and Amyloid Toxicity in

APP/PS1 Mice

New Investigator Research Grant—\$98,997 over two years What influence does folate deficiency have on levels of an essential brain chemical and amyloid toxicity in Alzheimer-like mice?

• Mathieu Lesort, Ph.D.

University of Alabama at Birmingham Birmingham, Alabama

Pathological Interactions in Diabetes and Alzheimer's Disease Investigator-Initiated Research Grant—\$200,000 over three years Does diabetes-induced chemical changes to tau predispose the brain to Alzheimer pathology?

• Brenda L. Plassman, Ph.D.

Duke University Medical Center Durham, North Carolina Middle- and Late-Life Predictors of Alzheimer's Disease in Elderly Twins

Investigator-Initiated Research Grant—\$198,363 over three years Can cardiovascular risk factors of Alzheimer's disease be better characterized by comparing outcomes among twins?

• Dorene M. Rentz, Psy.D.

Brigham and Women's Hospital, Inc. Boston, Massachusetts

Amyloid Deposition in Normal Controls: Impact of Cognitive Reserve Investigator-Initiated Research Grant—\$239,569 over three years Does a presumed cognitive reserve provide a protective effect in people with imaging-detected beta-amyloid deposits?

• Nicole Schupf, Ph.D.

Columbia University Medical Center

New York, New York

Genetics of Estrogen and Alzheimer's Disease in a Multiethnic Cohort Investigator-Initiated Research Grant—\$239,999 over three years Do variant forms of genes related to estrogen production increase the risk of Alzheimer's disease?

• Kristine Yaffe, M.D.

University of California, San Francisco San Francisco, California

Predictors of Mild Cognitive Impairment/Dementia Among the Oldest Old Women

Investigator-Initiated Research Grant—\$240,000 over three years What factors increase the risk of dementia in women in their 80s and 90s?

Diagnosis and disease monitoring

1. Biomarkers

• Gilbert T. Feke, Ph.D. Retina Associates, Inc.

Boston, Massachusetts

Objective Biomarkers for Alzheimer's Disease in the Retina

Investigator-Initiated Research Grant—\$239,390 over three years Can changes in the retina provide an early indication of cognitive impairment?

- Andras L. Palotas, M.D., Ph.D.
 - Asklepios-Med Bt.

Szeged, Hungary

Early Diagnosis Using Fibroblasts and Lymphocytes in Alzheimer's Disease

New Investigator Research Grant—\$97,912 over two years Can variant genes associated with white blood cells or connective tissue cells indicate a risk or the onset of Alzheimer's disease?

• Calin I. Prodan, M.D.

University of Oklahoma Health Science Center Oklahoma City, Oklahoma

Coated Platelets: A Potential Biomarker for Alzheimer's Disease New Investigator Research Grant—\$99,968 over two years Can a certain subset of blood platelets serve as a marker of Alzheimer's disease onset and progression?

• Chengjie Xiong, Ph.D.

Washington University in St. Louis St. Louis, Missouri

The Earliest Antecedent Markers of Alzheimer's Disease New Investigator Research Grant—\$99,956 over two years

Can a combination of disease markers be identified that provide a clinically useful measure of Alzheimer's disease risk or onset?

2. Brain imaging

• Mark Bondi, Ph.D.

University of California, San Diego

San Diego, California

Functional Neuroanatomy of Memory in Elders: a Combined FMRI and DTI Study

Investigator-Initiated Research Grant—\$239,988 over three years Can functional magnetic resonance imaging and diffusion tensor imaging identify patterns of brain changes in people at high risk for Alzheimer's?

• Jason E. Gestwicki, Ph.D.

University of Michigan

Ann Arbor, Michigan *Chemical Probes for Selective Recognition of Amyloid Oligomers* New Investigator Research Grant—\$99,813 over two years Can an imaging agent selectively identify only small aggregates of betaamyloid in the brain?

• William Jagust, M.D.

University of California, Berkeley

Berkeley, California

The Detection of Alzheimer's Disease in Normal Older People Zenith Fellows Award—\$449,999 over three years

Can a combination of imaging studies identify healthy older adults in nonsymptomatic early stages of Alzheimer's disease?

• Ricardo Maccioni, Ph.D.

International Center for Biomedicine Santiago, Chile In Search of Tau-Binding Molecules With Potential Clinical Applications

Investigator-Initiated Research Grant—\$238,800 over three years Can a tau-binding agent be identified that could be used in imaging studies to measure tau pathology?

• Pedro Rosa-Neto, M.D., Ph.D.

McGill University Montreal, Canada Glutamatergic Abnormalities in Patients With Early Alzheimer's Disease

New Investigator Research Grant—\$98,000 over two years Can increased levels of a cell-surface protein associated with Alzheimer's disease be detected with brain imaging?

• Youssef Zaim Wadghiri, Ph.D.

New York University School of Medicine New York, New York

Susceptibility-Based MRI Detection of Alzheimer's Amyloid Investigator-Initiated Research Grant—\$240,000 over three years Can a chemical probe used with magnetic resonance imaging enable researchers to measure levels of beta-amyloid in the brains of Alzheimer-like mice?

3. Other diagnostic studies

• Vladimir Hachinski, Ph.D.

Lawson Health Research Institute London, Canada

Risk Score Development to Predict Alzheimer's Disease and Dementia Investigator-Initiated Research Grant—\$238,770 over three years Can a risk assessment tool identify people at increased risk of developing Alzheimer's disease?

• Hochang Lee, M.D.

Johns Hopkins University School of Medicine Baltimore, Maryland

Assessment of Burden of Dementia Among Korean Elders in Maryland

Investigator-Initiated Research Grant—\$240,000 over three years Can a Korean-language assessment tool improve the diagnosis of dementia in Korean-Americans?

• Michael D. Lee, Ph.D.

University of California, Irvine Irvine, California

Bayesian Methods for the Detection, Diagnosis and Treatment of Alzheimer's

New Investigator Research Grant—\$87,726 over two years What imaging, clinical and cognitive tests most accurately diagnose Alzheimer's disease and measure its severity?

• Adriana Macias Strutt, Ph.D.

Baylor College of Medicine Houston, Texas

Validation of a Spanish Neuropsychological Dementia Battery New Investigator Research Grant—\$99,715 over two years Can a comprehensive test for dementia be validated for Spanishspeaking individuals in the United States?

Drug development and clinical interventions

1. Anti-amyloid therapies

• Yona Levites, Ph.D.

Mayo Clinic

Jacksonville, Florida

Single Chain Fragments as a Tool to Target Generic Amyloid New Investigator Research Grant—\$100,000 over two years Can an anti-amyloid antibody be designed that specifically targets small, toxic beta-amyloid aggregates in Alzheimer-like mice?

• Philip Williams, Ph.D.

University of Hawaii

Honolulu, Hawaii

Medicines From Marine Sources

New Investigator Research Grant—\$99,977 over two years Can chemicals isolated from sponges and marine bacteria inhibit a key protein in beta-amyloid production?

• Muralikrishnan Dhanasekaran, Ph.D.

Auburn University Auburn, Alabama

Novel Neuroprotective Effects of Centella asiatica

New Investigator Research Grant—\$99,990 over two years By what mechanism does an Asian medicinal plant decrease betaamyloid levels in Alzheimer-like mice?

- Valentina Echeverria Moran, Ph.D.
 - Bay Pines Foundation, Inc.

Bay Pines, Florida *Molecular Mechanisms Underlying the Neuroprotective Actions of Cotinine* New Investigator Research Grant—\$100,000 over two years Can a chemical derived from nicotine prevent the formation of toxi

Can a chemical derived from nicotine prevent the formation of toxic beta-amyloid structures in Alzheimer-like mice?

• Douglas L. Feinstein, Ph.D.

University of Illinois – Chicago Chicago, Illinois

Anti-amyloidogenic Effects of Noradrenaline Investigator-Initiated Research Grant—\$239,999 over three years Does a drug that boosts levels of certain brainstem cells have an antiamyloid effect and other therapeutic effects on Alzheimer-like mice?

• Veronica Galvan, Ph.D.

University of Texas Health Sciences Center San Antonio, Texas

Small-Molecule Inhibitors of Asp664 Cleavage of APP New Investigator Research Grant—\$148,660 over two years Can a molecule be identified that inhibits a particular protein-protein interaction that helps initiate beta-amyloid production?

• Bonnie Goodwin, Ph.D.

University of South Florida

Tampa, Florida Gamma-Secretase Inhibitors Induce Cell Cycle Defects and Chromosome Aneuploidy

New Investigator Research Grant—\$100,000 over two years What is the effect of gamma-secretase inhibition on normal cellular functions?

• Michael Hecht, Ph.D.

Princeton University Princeton, New Jersey

Discovery of Compounds that Prevent A-Beta Toxicity Investigator-Initiated Research Grant—\$239,993 over three years Can a compound be identified that blocks the aggregation of betaamyloid in cultured cells and in a roundworm model of beta-amyloid aggregation?

• Ashok N. Hegde, Ph.D.

Wake Forest University Winston-Salem, North Carolina Ameliorating Harmful Abeta Effects on Synaptic Plasticity and Memory

Investigator-Initiated Research Grant—\$240,000 over three years Can an experimental drug inhibit the action of beta-amyloid on synaptic function?

• Louis B. Hersh, Ph.D.

University of Kentucky Lexington, Kentucky

A Modified Neprilysin for Gene Therapy

Investigator-Initiated Research Grant—\$238,936 over three years Does an engineered version of a beta-amyloid–degrading brain enzyme have a disease-modifying effect in Alzheimer-like mice?

Daniel Paris, Ph.D.

Roskamp Institute

Sarasota, Florida

Effect of Celastrol in a Transgenic Mouse Model of

Alzheimer's Disease

Investigator-Initiated Research Grant—\$200,000 over three years Does a compound derived from an Asian medicinal plant have a diseasemodifying effect in Alzheimer-like mice?

• Peter M. Tessier, Ph.D.

Rensselaer Polytechnic Institute Troy, New York

Molecular Mechanisms of Abeta Aggregation Inhibitors

New Investigator Research Grant—\$100,000 over two years By what mechanism does a certain class of compounds inhibit the aggregation of beta-amyloid molecules?

• Mark H. Tuszynski, Ph.D.

University of California, San Diego La Jolla, California

Therapeutic Effects of BDNF in APP Mutant Mice

Investigator-Initiated Research Grant—\$240,000 over three years Does brain-derived neurotrophic factor (BDNF) prevent neuron loss, preserve neuron function and improve behavioral changes in mice with amyloid precursor protein mutations?

• Jerry C. Yang, Ph.D.

University of California, San Diego La Jolla, California

Exploring Methods to Chemically Degrade Aggregated Abeta Peptides

New Investigator Research Grant—\$100,000 over two years Can experimental compounds degrade small, toxic aggregates of betaamyloid in cultured cells?

2. Nutritional therapies

• Nancy B. Emerson Lombardo, Ph.D. Boston University

Bedford, Massachusetts

Nutritional Supplement Clinical Trial for Early Alzheimer's (MPNSP) Investigator-Initiated Research Grant—\$240,000 over three years Does a combination of nutritional supplements have a treatment effect in

people with early-stage Alzheimer's disease?

• Donald K. Ingram, Ph.D.

Louisiana State University Agricultural and Mechanical College Baton Rouge, Louisiana

Developing Calorie Restriction Mimetics for Treating Alzheimer's Disease

Investigator-Initiated Research Grant—\$239,426 over three years Can drugs that mimic the effect of a low-calorie diet delay cognitive decline in Alzheimer-like mice?

• Thomas B. Shea, Ph.D.

University of Massachusetts, Lowell

Lowell, Massachusetts

A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

Investigator-Initiated Research Grant—\$237,449 over three years Does a nutritional supplement have a beneficial effect on cognitive function in people with Alzheimer's disease?

3. Other therapies

• Fortunato Battaglia, Ph.D.

City College of New York and the Research Foundation of City University of New York New York, New York

Boosting Memory in APP/PS1 Mice With Transcranial Magnetic Stimulation

New Investigator Research Grant—\$99,000 over two years Can magnetic stimulation of brain cell activity restore normal function and biochemistry of synapses in Alzheimer-like mice?

• David H. Cribbs, Ph.D.

University of California, Irvine

Irvine, California

Reducing the Risk of Cerebral Vascular Adverse Events in Alzheimer's Disease

Investigator-Initiated Research Grant—\$240,000 over three years Can treatments reduce the effect of amyloid-induced damage to brain blood vessels in Alzheimer-like mice?

• Orestes Forlenza, Ph.D.

University of São Paulo São Paulo, Brazil *Disease-Modifying Properties of Lithium in Alzheimer's Disease* New Investigator Research Grant—\$100,000 over two years Can lithium treatment delay the onset of Alzheimer's disease in people with mild cognitive impairment?

Pamela A. Maher, Ph.D.
The Solly Institute for Diplosic

The Salk Institute for Biological Studies La Jolla, California

Fisetin and derivatives as Neuroprotective Drugs for Alzheimer's Disease

Investigator-Initiated Research Grant—\$240,000 over three years Can a new form of the natural product fisetin protect neurons and enhance memory in Alzheimer's?

• Prasad R. Padala, M.D.

University of Nebraska Medical Center Omaha, Nebraska

Improving Function, Quality of Life and Glycemia in Diabetics With Dementia

New Investigator Research Grant—\$98,690 over two years Can a drug that reduces apathy improve blood sugar level control and quality of life in people with diabetes and dementia?

• Martin J. Sadowski, M.D., Ph.D.

New York University School of Medicine New York, New York

Therapeutic Monoclonal Antibodies for Prion Exposure Prophylaxis Investigator-Initiated Research Grant—\$240,000 over three years Can an antibody block the spread of abnormal prions in mice with prioninduced neurodegeneration?

• Moussa Youdim, Ph.D.

Technion–Israel Institute of Technology Haifa, Israel Novel Neuroprotective and Neurorestorative Drugs for Alzheimer's Disease

Investigator-Initiated Research Grant—\$297,000 over three years Can iron-binding drugs protect and restore nerve cells in mice with an Alzheimer-like pathology?

Care, support and social-behavioral factors

1. Nursing homes, assisted living residences and dementia care units

• Kathryn de Medeiros, Ph.D.

Copper Ridge Institute

Sykesville, Maryland

The Social Environments of People With Dementia in Long-Term Care

New Investigator Research Grant—\$99,389 over three years What factors influence the quality of social relationships in dementia care facilities?

Sharon K. Inouye, M.D.

Hebrew Rehabilitation Center for the Aged Boston, Massachusetts

Impact of Hospitalization in Alzheimer's Disease: Risk Factors and Outcomes

Investigator-Initiated Research Grant—\$240,000 over three years What are the risk factors for hospitalization and the outcomes of hospital care in people with Alzheimer's disease?

• Susan C. Miller, Ph.D.

Brown University

Providence, Rhode Island

End-of-Life Care and Hospice: Older Adults With Dementia in Nursing Homes

Investigator-Initiated Research Grant—\$198,963 over three years What is the quality and extent of hospice care available to nursing home residents with late-stage dementia?

• Quincy M. Samus, Ph.D.

Johns Hopkins University School of Medicine Baltimore, Maryland

Specialization of Dementia Care Assisted Living: A Pilot Project

New Investigator Research Grant—\$100,000 over two years How does quality of care differ between general care and dementiaspecific care in assisted living facilities?

2. Care interventions and quality of life

• David M. Bass, Ph.D.

Benjamin Rose Institute

Cleveland, Ohio

Partners in Dementia Care

Investigator-Initiated Research Grant—\$239,811 over three years Can a collaborative care program of the Veterans Administration and the Alzheimer's Association improve care for U.S. veterans?

• Michelle Bourgeois, Ph.D.

Ohio State University Columbus, Ohio

Determining Quality of Life in Dementia With Visual and Written Stimuli

Investigator-Initiated Research Grant—\$200,000 over three years Can visual and verbal techniques help people with dementia answer quality-of-life questions? Dolores E. Gallagher-Thompson, Ph.D. Stanford University Stanford, California Development and Evaluation of a Fotonovela to Manage Difficult Behaviors

Investigator-Initiated Research Grant—\$240,000 over three years Is a fotonovela an effective tool for training Latino caregivers to manage problem behaviors and neuropsychiatric symptoms?

• Judith G. Gonyea, Ph.D.

Boston University

Boston, Massachusetts

Circulo de Cuidado: A Behavioral Group Intervention for Latino Families

Investigator-Initiated Research Grant—\$239,080 over three years Can a group behavioral intervention program for Latino caregivers minimize behavioral and neuropsychiatric symptoms in people with Alzheimer's disease?

• McKee J. McClendon, Ph.D.

Case Western Reserve University Cleveland, Ohio

Quality of Caregiving in Alzheimer's Disease

Investigator-Initiated Research Grant—\$239,996 over three years How do a caregiver's skills, emotional health and caregiving style affect the quality of life of a person with dementia?

• Joann Reinhardt, Ph.D.

Jewish Home and Hospital for the Aged New York, New York

Enhancing Life Quality for Residents With End-Stage Dementia

and Families

Investigator-Initiated Research Grant—\$237,067 over three years How does an interdisciplinary care model maximizing physical and psychosocial comfort affect the quality of life for people with end-stage dementia?

• Robert A. Stern, Ph.D.

Boston University Medical Campus Boston, Massachusetts

Assessment of Driving Safety in Aging, Mild Cognitive Impairment and Dementia

Investigator-Initiated Research Grant—\$239,999 over three years Can a combination of office-based tests accurately predict safe driving skills in people with mild cognitive impairment and dementia?

• Angelo Volandes, M.D.

Massachusetts General Hospital

Boston, Massachusetts

Using Video Images of Dementia in Advanced Care Planning New Investigator Research Grant—\$96,844 over two years Can video depictions of advanced dementia help people with early-stage dementia make long-term care plans?

3. Technology-assisted care

• Arlene Astell, Ph.D.

University of St. Andrews

St. Andrews, United Kingdom

Prompting to Support Independence in Dementia

Everyday Technologies for Alzheimer Care Grant —\$179,634 over two years

What kind of electronic prompts can assist people with dementia with such tasks as cooking or keeping track of appointments?

• Holly B. Jimison, Ph.D.

Oregon Health & Science University Portland, Oregon *Cognitive Health Coaching for Elders in a Home Environment* Everyday Technologies for Alzheimer Care Grant —\$189,842 over two years Can a computer-based coaching tool improve the management of physical exercise, nutrition and sleep for people with dementia?

• Alex Mihailidis, Ph.D.

University of Toronto Toronto, Ontario, Canada *Toward a Pervasive Prompting System: Improving and Expanding the COACH* Everyday Technologies for Alzheimer Care Grant —\$196,324 over three years Can an electronic prompting tool assist people with dementia in performing everyday self-care activities?

Pascal Poupart, Ph.D.

University of Waterloo Waterloo, Ontario, Canada Composite Behavioral Markers to Assess and Monitor Alzheimer's Disease Everyday Technologies for Alzheimer Care Grant —\$200,000 over three years Can sensors detect behaviors that enable the monitoring of behavioral symptoms of Alzheimer's disease?

4. Caregiver support

• Ilene Siegler, Ph.D.

Duke University Medical Center Durham, North Carolina *Culture and the Emotional Health of Black and White Alzheimer's Disease Caregivers*

Investigator-Initiated Research Grant—\$238,729 over three years How do cultural and social factors influence the emotional health of caregivers?